Confo Therapeutics And DyNAbind Announce Drug Discovery Collaboration To Identify Novel GPCR-Modulating Compounds

Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH recently announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR).

The collaboration will combine ConfoBodyTM-enabled GPCRs with DyNAbind’s Dynamic DNAencoded Library for the discovery of small molecule GPCR-modulating compounds. Under the terms of the agreement, Confo Therapeutics will gain exclusive, worldwide rights to any drug candidates arising from the collaboration and will be responsible for their development, manufacturing and commercialization.

Commenting on the deal, Dr Christel Menet, Confo Therapeutics’ CSO, said: “This collaboration will leverage the combination of two cutting-edge technologies to expand our universe of hits on a GPCR previously thought to be intractable. We look forward to working with the DyNAbind team on this exciting project.”

Dr Michael Thompson, co-founder and CEO of DyNAbind added: “GPCRs are high-potential targets for drug discovery, but have been traditionally difficult to work with. Confo Therapeutics’ technology has proven itself to be a powerful tool for the stabilization of GPCRs in a particular conformation. Partnered with the increased signal-to-noise ratios seen with our Dynamic Library technology, we are in a strong position to identify drug candidates against this specific target. ”